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Abstract 
MicroRNAs (miRs) play an important role in the development of many complex human 
diseases and may have tumour suppressor or oncogenic (oncomir) properties. Prostate cancer is 
initially an androgen-driven disease, and androgen receptor (AR) remains a key driver of 
growth even in castration-resistant tumours. However, AR-mediated oncomiR pathways remain 
to be elucidated. We demonstrate that miR-27a is an androgen-regulated oncomir in prostate 
cancer, acting via targetting the tumour suppressor and AR corepressor, Prohibitin (PHB). 
Increasing miR-27a expression results in reduced PHB mRNA and protein levels, and 
increased expression of AR target genes and prostate cancer cell growth. This involves a novel 
mechanism for androgen-mediated miR regulation, whereby AR induces a transient increase in 
miR-23a27a24-2 transcription, but more significantly accelerates processing of the primiR-
23a27a24-2 cluster. Androgens therefore regulate miR-27a expression both transcriptionally 
(via AR binding to the cluster promoter) and post-transcriptionally (accelerating primiR 
processing to the mature form). We further show that a miR-27a anti-sense oligonucleotide, by 
opposing the effects of mir-27a, has therapeutic potential in prostate cancer. 
3 
	  
Introduction 
Prostate cancer (PCa) is the most prevalent non-cutaneous malignancy in Western males (1). 
Initially, growth of prostate tumours is dependent on circulating androgens, which exert their 
growth-stimulatory effects through association with the androgen receptor (AR) (2). AR is a 
ligand-dependent transcription factor, activation of which by androgens initiates target gene 
transactivation resulting in PCa cell proliferation. This involves dimerization and recruitment 
to androgen response elements (AREs) of coactivators and/or corepressors (3-7), whose roles 
in PCa remain poorly understood. MicroRNAs (miRs), which have been shown to function as 
oncogenes and tumour suppressors in multiple cancers (8-11), may play an important role in 
PCa through targeting coregulators of AR and targets involved in growth response. Further, 
several miRs demonstrate androgen regulation, although the mechanisms surrounding such 
regulation remain to be elucidated. In this study, we demonstrate inhibition of the AR 
corepressor, Prohibitin (PHB), by hsa-miR-27a (henceforth referred to as miR-27a) in PCa, 
and identify a mechanism by which AR mediates post-transcriptional miR-27a maturation. 
Importantly, as well as being an AR corepressor, PHB is an AR target protein, 
downregulation of which promotes cell growth, implying a tumour suppressor function (12-
14). How much of this relates to its corepressor role is not clear. Thus, miRs that inhibit AR 
targets and/or coregulators to modulate androgen response may represent novel targets for 
PCa therapeutics. 
PHB is an evolutionarily conserved protein with multiple cellular functions (15-22) 
that negatively regulates AR activity and androgen-stimulated growth of PCa cells (13). A 
reduction in PHB either by androgens or RNAi-mediated knockdown resulted in increased 
AR activity and enhanced growth of prostate xenografts (LNCaP) (14). Our initial 
observation that AR downregulates PHB was followed by evidence that this occurs at least 
partly at the level of transcription. Indeed, PHB regulation may involve several mechanisms, 
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such as genomic effects at the PHB promoter or post-translational modifications. A more 
recent hypothesis suggests a role for miR association with PHB 3’UTR in regulation of PHB 
(23). However, the precise mechanism of androgen or AR-mediated downregulation of genes 
such as PHB is unknown. Interestingly, we found that the optimum RNAi oligo for PHB 
knockdown shared considerable sequence similarity to a previously published oncomiR 
targeting PHB-3’UTR – namely miR-27a (23). PHB has a large, highly conserved 3’UTR, 
with several putative miR binding sites, indicating that miRs may be heavily involved in its 
regulation. 
MiRs are 19-25nt non-coding RNAs that regulate target gene expression through 
translational inhibition or transcript degradation (24), regulating a wealth of biological 
processes including tumourigenesis (25). Further, approximately 50% of miR genes are in 
cancer-associated genomic regions or in fragile sites (26). It is, therefore, conceivable that 
miRs have a significant effect on cell physiology and that common single-nucleotide 
polymorphisms (SNPs) within key miR target sites could contribute significantly to an 
individual’s risk of developing complex diseases. Functional studies have also established 
that individual miRs can act as oncogenes (oncomiRs) or tumour supressors (8), and although 
targets of many miRs remain to be elucidated, some have been shown to repress well-known 
oncogenes or tumour supressors. For example, miR-15/16 inhibit the anti-apoptotic factor 
BCL2, an anti-apoptotic factor (27), while the let-7 family of miRs target the Ras oncogene 
(28). Thus, miR aberrations may be involved in prostate oncogenesis and development of 
castration resistant PCa (CRPC) (10, 29, 30). Several studies have revealed distinct miR 
signatures in prostate tumours compared to benign samples (11, 31, 32). 
MiR-27a is encoded in an intergenic cluster with miR-23a and miR-24-2 located on 
chromosome 19p13.1. The ~2159nt primary transcript is transcribed from a promoter region 
located between -603 and +36nt (33). The -530 to -410 promoter portion contains two GC-
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rich domains and is thought to be the location for transcription factor binding (34, 35). 
Expression of the miR23a27a24-2 cluster is altered in many cancers, including leukemia (36, 
37), breast cancer (38), colorectal cancer (39), hepatocellular carcinoma (40), ovarian cancer 
(41) and PCa (11, 32). Upregulation of this cluster has been shown to reduce tumour 
suppressive effects of TGFβ in human hepatocellular carcinoma cells (40); conversely, it 
induced apoptosis in human embryonic kidney cells (42). The diverse effects of this cluster 
suggest context-dependent activities, warranting investigation into the individual molecular 
functions of the cluster members and identification of targets, especially given evidence of 
differential regulation of miR-23a27a24-2 cluster members. For example, downregulation of 
miR-27a has been observed independently of miR-23a and miR-24-2 (43), and it is likely that 
both transcriptional and post-transcriptional mechanisms may be involved in cluster 
regulation.  
As miR-27a has been proposed to function as an oncomiR in gastric cancer through 
downregulation of PHB (23) and given the androgen-mediated downregulation of PHB and 
the role of PHB in AR repression, we hypothesised that the AR itself may modulate levels of 
miR-27a thus downregulating its own repressor (PHB) in a ‘positive feedback loop’. MiR-
27a targeting of PHB could play an important role in PCa progression in several ways; 
through reducing AR repression and by downregulating other repressive roles of PHB, 
resulting in maintenance of oncogenic phenotype.  
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Results 
Androgen Regulation of PHB Occurs Largely at the 3’UTR 
In the LNCaP PCa cell line, androgen treatment reduces PHB levels by approximately 50% 
(13). However, PHB promoter activity shows a maximum reduction of only 25% following 
AR activation (Fig S1), therefore we hypothesised that androgen regulation of PHB may 
occur at the 3’UTR. PHB-3’UTR sequence was fused to a luciferase reporter (Fig S1B+C) 
and HeLa cells were transiently transfected with this reporter and AR expression vector. 
Luciferase activity was reduced by approximately 25% upon androgen treatment (Fig 1A), 
supporting the hypothesis that androgens downregulate PHB via the 3’UTR. This is mediated 
by AR, since AR silencing (using a doxycycline-inducible system (44)), resulted in increased 
PHB-3’UTR levels, which was not observed using scrambled shRNA (Fig 1B). In further 
support of a role for the 3’UTR in androgen regulation of PHB, when another PCa cell line, 
PC3wtAR cells, were treated with androgen and primer-specific qRT-PCR performed for 
either the PHB coding region or PHB-3’UTR, reduction in PHB 3’UTR was 85% compared 
to 45% for the coding region (Fig 1C). Finally, anti-androgen treatment abrogated the effects 
of MB at the endogenous PHB-3’UTR: whilst PHB-3’UTR PCR product levels were 
drastically reduced following androgen treatment of LNCaP cells (Fig 1D), addition of 
Bicalutamide (Bic) reversed this effect. These data suggest that androgen exerts inhibitory 
effects on PHB via the 3’UTR.  
PHB is a Target of MiR-27a in PCa Cells 
Putative miR binding sites in the PHB-3’UTR were mapped (microRNA.org) (Fig S2) and 
showed eight groupings within the 3’UTR, including a binding site for miR-27a, of interest 
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due to its reported role as an oncomiR targeting PHB in gastric cancer (23). High sequence 
complementarity exists between PHB 3’UTR and the miR-27a seed region (Fig 2A). To 
confirm that PHB-3’UTR contains bona fide miR-27a target sequences, the PHB 3’UTR 
reporter vector was transfected into HeLa cells with expression vectors for AR and miR-27a 
mimic (p2TetR-miR-27a: since HeLa cells lack Tet repressor, doxycycline (dox) was not 
required to derepress miR-27a mimic expression). A mutant form of the PHB-3’UTR was 
also tested, carrying two nucleotide changes in the putative miR-27a seed region (Fig 2A). 
Whilst addition of miR-27a mimic resulted in 60% reduction in PHB-3’UTR activity, it did 
not significantly alter activity of the mutated reporter (Fig 2B), demonstrating that PHB-
3’UTR is a direct target of miR-27a via this site. To assess whether miR-27a can reduce 
levels of endogenous PHB in PCa cells, LNCaP cells expressing miR-27a under dox control 
were created (LNCaP/TR2/miR-27a). Induction of exogenous miR-27a mimic resulted in a 
considerable reduction in PHB protein levels 24h post dox treatment compared to non-
induced cells, with optimal 90% reduction in PHB protein observed following 0.1µM dox 
treatment (Fig 2C). To address the physiological relationship between endogenous miR-27a 
and PHB in PCa, PHB protein and miR-27a levels were assessed by Western blotting and 
qRT-PCR respectively in a panel of representative human cell line models.  A significant 
inverse correlation between PHB protein levels and miR-27a levels was found, with a 
Pearson correlation coefficient of -0.881. This suggests that levels of PHB and miR-27a are 
closely linked in PCa, supporting PHB as an endogenous target of miR-27a in this disease.  
To investigate whether repression of PHB-3’UTR is via translational repression or 
transcript degradation, levels of PHB-3’UTR were assessed by qRT-PCR in 
LNCaP/TR2/miR-27a cells induced with dox. Increasing miR-27a levels resulted in up to 
70% reduction in PHB-3’UTR levels (representing the complete mRNA) compared to 
untreated cells (Fig 2E). This suggests that miR-27a induces degradation of the PHB 
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transcript following binding to the PHB-3’UTR. To confirm whether these effects on PHB 
are specifically attributable to miR-27a, miR-27a anti-sense oligonucleotide (ASO) was 
transfected into LNCaP cells in the presence or absence of miR-27a. In agreement with 
Figure 2C, miR-27a significantly reduced PHB protein levels by up to 70% (Fig 2F). 
Addition of ASO rescued miR-27a-mediated PHB loss, while transfection of ASO alone 
increased PHB protein levels approximately 2.6-fold. Next, the impact of ASO introduction 
on PHB-3’UTR activity was assessed in HeLa cells. MiR-27a reduced PHB-3’UTR activity 
by approximately 60% and this was restored to empty vector-transfected control levels upon 
addition of 1-10µg ASO, in a dose-dependent manner (Fig 2G). Further, transfection of the 
ASO into LNCaP cells increased PHB-3’UTR transcript levels compared to untransfected or 
scrambled control-transfected cells, presumably by acting on endogenous miR-27a (Fig 2H). 
Taken together, these data confirm that miR-27a targets PHB-3’UTR in PCa cells through 
seed region binding, leading to transcript disruption and/or translational inhibition and loss of 
PHB protein, which can be abrogated through addition of miR-27a ASO. 
MiR-27a Overexpression Results in Increased Expression of Androgen-Regulated 
Genes and Increases PCa Cell Growth  
Since PHB is an AR corepressor, the impact of PHB reduction on expression of PSA and 
TMPRSS2 (well-characterised AR-responsive genes) was examined by qRT-PCR after dox 
induction of LNCaP/TR2/p2TetR-miR-27a cells. PSA and TMPRSS2 mRNA levels were 
increased up to 3.2-fold following induction of exogenous miR-27a expression (Fig 3A). To 
investigate effects of miR-27a on LNCaP PCa cell growth, the same cells were treated with 
10nM MB ± dox, and cell number assayed at intervals up to 6 days. Androgen treatment 
increased cell growth 1.5-fold compared to vehicle-treated control cells at 6 days (Fig 3B). 
Exogenous expression of miR-27a mimic (Dox + MB) resulted in a significantly greater, 1.7-
fold increase in cell growth compared to vehicle-treated control cells at 6 days. Induction of 
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miR-27a mimic in androgen-depleted medium did not increase cell growth, suggesting that 
miR-27a plays a role in androgen-dependent growth. To investigate whether the growth-
stimulatory effects of miR-27a could be specifically attributed to targeting of PHB, a plasmid 
expressing tagged PHB (pcDNA4/TO-GFP-PHB) was introduced into the above system. It 
was found that increasing PHB resulted in decreased cell growth even in the presence of 
exogenous miR-27a (Fig 3B: note that non-normalised data is shown on the right to illustrate 
the effect of miR-27a on growth in the presence of androgen), i.e. PHB can indeed suppress 
miR-27a-mediated growth stimulation. Induction of miR-27a expression and GFP-PHB 
transfection did not alter cell growth in the absence of MB (Fig S3). In a reciprocal 
experiment, stable LNCaP/GFP-PHB cells were transfected with miR-27a or a negative 
control oligo and treated with MB ± dox to induce GFP-PHB expression (Fig 3D). In 
agreement with Fig 3B, it was found that miR-27a overexpression in the absence of 
exogenous PHB led to a significant 80% increase in androgen-induced cell growth. In 
contrast, upon induction of GFP-PHB expression, no significant difference was observed 
between miR-27a-transfected and non-transfected cells, suggesting that overexpression of 
PHB is able to compensate for the growth increase induced by miR-27a of PHB 3’UTR. It 
should be noted that the exogenous PHB lacks the 3’-UTR hence would not be targeted by 
miR-27a. These data suggest that the growth-stimulatory effects of miR-27a in PCa cells are 
largely attributable to miR-27a targeting of PHB, without ruling out a contribution of other 
miR-27a-regulated transcripts. 
  As miR-27a increased PCa cell growth, we hypothesised that miR-27a ASO may 
inhibit proliferation. In support of this, whilst androgen treatment of LNCaP cells transfected 
with scrambled ASO gave a three-fold increase in cell number after 6 days, the increase was 
reduced to 1.5-fold in cells transfected with miR-27a ASO in the presence of androgen (Fig 
3E). Together these data indicate that miR-27a targeting of PHB increases AR activity in PCa 
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cells through loss of PHB corepressive activity, and that manipulation of miR-27a alters PCa 
cell growth.  
The MiR-23a27a24-2 Cluster is Regulated by Androgen and AR in PCa Cells  
Since both androgen signalling and miR-27a downregulate PHB, we investigated whether 
miR-27a is androgen regulated. LNCaP cells were treated with 10nM MB or ethanol for 0-
24h and endogenous mature miR-27a assayed by qRT-PCR. MiR-27a expression increased 
by >2-fold after 4h and by 2.9-fold after 24h in LNCaP cells treated with MB, compared to 
time zero (P≤0.05, Fig 4A). This is consistent with the magnitude of fold-increases reported 
in microarray analysis of AR-regulated miRs in PCa (11).  
As miR-27a is polycistronically transcribed (Fig 4B), we next examined whether 
miR-27a cluster partners, miR-23a and miR-24-2 demonstrate androgen regulation. qRT-
PCR was performed for mature miRs 27a, 23a and 24-2 following treatment of LNCaP cells 
with androgen and an anti-androgen (Bic). All three miRs were significantly increased 
following MB treatment, but decreased to near-vehicle control levels upon addition of anti-
androgen. (Fig 4C). The extent of regulation varied for the three cluster members, with miR-
27a demonstrating a greater response to MB (5-fold increased expression) compared to miR-
23a and miR-24 (3.8-fold and 2-fold respectively). These changes in mature miR levels are 
confirmed as AR-specific as they can be negated by anti-androgen treatment. To confirm that 
androgen regulation of miR-27a is not a cell line-specific effect, PC3wtAR cells (45) were 
treated with MB ± Bic for 24 hours followed by Northern blotting of total RNA (Fig 4D). 
Again, androgen treatment increased miR-27a levels in a dose-dependent manner, and this 
was abrogated by anti-androgen treatment.  
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AR Associates with the Proximal MiR23a27a24-2 Promoter in PCa Cells in Response to 
Androgen Treatment to Enhance Transcription and also acts to Enhance Drosha-
Mediated PrimiR-23a27a24-2 Processing  
The observation that all three members of the miR-23a27a24-2 cluster demonstrate androgen 
regulation suggested this may be mediated through association of liganded AR with AREs 
within the cluster promoter. We used the ALGGEN algorithm (http://alggen.lsi.upc.es/) to 
predict putative AREs or half-sites within the miR-23a27a24-2 promoter. Two predicted 
AREs were identified within 300bp 5’ of the miR-23a27a24-2 transcription start site (Fig 
S3A). To assess whether the proximal miR promoter can confer androgen responsiveness 
upon a luciferase reporter gene, indicative of primiR transcription, an 800bp proximal portion 
(-726 to -23) and a 1.1kb distal portion (-2982 to -1942) of the miR cluster promoter were 
inserted upstream of the luc2 gene in the pGL4.18 vector and transfected intoos-1 cells 
alongside AR expression vector. Activity of the proximal fragment was increased five-fold 
following androgen treatment compared to vehicle-treated cells (Fig 5A), however miR distal 
promoter activity was unchanged, suggesting this region is not androgen responsive. To 
assess whether liganded AR can directly associate with the proximal miR cluster promoter, 
ChIP analysis was performed on LNCaP cells following treatment with MB or vehicle for 0-2 
hours, using primers to amplify a 352bp portion of the proximal miR cluster promoter (Fig 
S4A). AR was significantly enriched by approximately 2.5-fold on the proximal miR cluster 
promoter in LNCaP cells after 30 minutes of androgen treatment compared to vehicle-treated 
cells (Fig 5B). However, association appears to be transient, as enrichment was reduced to 
basal levels after 60 and 120min of androgen treatment. The well-defined androgen-regulated 
PSA gene promoter was used as a positive control throughout ChIP experiments (Fig S4B-E). 
The above data suggest that AR is able to associate with the miR-23a27a24-2 promoter in 
response to androgen to initiate transcription of the cluster, albeit in a transient manner.  
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As miR-27a and its cluster partners are polycistronically transcribed and all 
demonstrate androgen regulation, we wished to confirm whether AR association with the 
miR-23a27a24-2 promoter leads to androgen-dependent transcription of the entire 
endogenous miR-23a27a24-2 cluster. LNCaP cells were treated with MB for 0-24 hours and 
qRT-PCR was performed using primers designed to amplify miR-23a27a24-2 primary 
transcript (primiR-23a27a24-2). PrimiR levels were increased 7-fold 1 hour post-androgen 
treatment, whereafter primiR levels declined until, after 24 hours of androgen treatment, 
primiR levels were similar to vehicle-treated cells (Fig 5C). MB-mediated AR activation 
across this time frame was confirmed by increased PSA expression (Fig S5). Together with 
Fig 4A, Fig 5C suggests that an initial peak in primiR levels is translated into later increase in 
mature miR levels, with the possibility that androgen treatment acts not only at the miR 
cluster promoter, but also to enhance pri-mir or pre-mir turnover. In corroboration of this, 
examination of primiR-23a27a24-2 levels following AR silencing revealed primiR 
accumulation, rather than loss, in PCa cells following induction of AR shRNA, whereas 
induction of scrambled shRNA had no effect on primiR levels (Fig 5D). These data indicate a 
further role for liganded AR in enhancing primiR/premiR processing, as AR-mediated miR 
promoter activation could not explain the observed decrease in primiR transcript levels 
following AR silencing. To investigate the ability of AR to enhance Drosha-mediated 
primiR-23a27a24-2 processing, we generated a reporter vector in which the genomic miR-
23a27a24-2 sequence is located 5’ of the luc2p gene, under the control of a CMV promoter. 
Transcription yields primiR-23a27a24-2 transcript linked to the luc2p transcript. Drosha-
mediated cleavage of the primiR disrupts the transcript, resulting in loss of luciferase activity 
- thus Drosha activity is inversely correlated with luciferase activity. This system has been 
shown to be a sensitive assay for Drosha-mediated cleavage of a specific primiR species in 
previous studies (46-48). The primiR-23a27a24-2 Drosha cleavage reporter was transfected 
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into Cos-1 cells alongside AR and increasing doses of MB and Bic. Luciferase activity was 
significantly reduced in the presence of MB with reference to vehicle-treated cells, 
suggesting that androgen treatment increased Drosha cleavage of primiR-23a27a24-2. 
Addition of Bic to this system was able to abrogate the effect of androgen treatment on 
Drosha activity, confirming that liganded AR is able to specifically enhance Drosha 
processing of primiR-23a27a24-2. These effects were not observed in the absence of AR (Fig 
S6A) or upon transfection of the empty CMV-GL4 plasmid (Fig S6B). 
AR Regulation of MiR-27a Occurs During Post-Transcriptional Processing of PrimiR to 
PremiR  
To confirm that androgen regulation of miR-27a occurs post-transcriptionally, we 
investigated the ability of miR-27a and its cluster partners to accumulate in the absence of 
active transcription through treatment of LNCaP cells with the transcription-blocking agent, 
Actinomycin D (ActD), ± androgen. We observed that after 6 hours treatment of cells with 
ActD and androgen, primiR levels were increased 6-fold due to the presence of MB prior to 
degradation of transcripts (Fig 6Ai). However, at later time points, primiR levels were 
drastically reduced due to transcriptional blocking and transcript degradation (Fig 6Ai). Of 
note: transcription of another androgen-regulated gene, KLK2, showed a similar decrease at 
24 and 48h post actinomycin treatment but without the initial peak at 6h, presumably due to 
different dynamics of AR regulation of this gene (Fig S7). In contrast to these primary 
transcripts, mature miR-27a levels were increased 6-fold at 48h post treatment (Fig 6Ai), 
showing a similar pattern of expression to that observed following androgen treatment in the 
absence of ActD (see Fig 4A). As expected, miR-27a levels were unchanged in the presence 
of ActD and ethanol (Fig 6Aii), likely due to lack of activated transcription and miR stability. 
L19 mRNA levels were significantly reduced by ActD treatment in the presence or absence 
of androgen, confirming transcriptional inactivation by ActD (Fig 6Aiii). These data suggest 
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that active transcription is not required to increase miR-27a levels following androgen 
treatment, and in combination with results shown in Fig 5E support the hypothesis that active 
androgen regulation of the miR cluster occurs during primiR to premiR processing. In 
confirmation of this, miR23a and miR24-2 are also increased in the presence of androgen, but 
not ethanol, following transcriptional inactivation (Fig 6B and 6C respectively). In contrast, 
miR-182, which we previously found to be unresponsive to androgen (data not shown), 
shows no difference in expression between vehicle and androgen treated cells following 
addition of ActD (Fig 6D). In addition, figures 6E and F show that, while primiR-23a27a24-2 
levels are reduced following 24h MB treatment (Fig 6E), mature miR-27a levels show the 
opposite, demonstrating a near 1.8-fold increase (Fig 6F). Treatment with the antiandrogen 
Bic abrogated both MB-induced primiR decrease and miR-27a increase. Addition of Bic 
alone did not alter miR-27a levels but led to a small increase in primiR levels, presumably 
due to stabilisation of the primiR. These data demonstrate that androgen treatment alters the 
equilibrium between primiR-23a27a24-2 and mature miR-27a, favouring accelerated miR-
27a production by enhancing Drosha-mediated primiR cleavage. To confirm that androgen-
enhanced post-transcriptional processing of primiR-23a27a24-2 requires AR, levels of mature 
miR-27a were assessed in LNCaP cells following dox-mediated induction of AR shRNA. 
Levels of miR-27a were 50% lower in PCa cells following AR silencing in the presence of 
androgen with reference to androgen only-treated cells (Fig 6F). This indicates that AR is 
required for androgen-induced primiR-23a27a24-2 to premiR-23a27a24-2 processing. 
Together these data indicate that androgen regulation of the miR-23a27a24-2 cluster 
occurs via two distinct processes. Initial regulation is at the level of transcription through 
transient association of AR with the miR cluster promoter, resulting in increased levels of the 
primiR. Additionally, androgens then promote Drosha-mediated primiR to premiR processing 
resulting in increased mature mir-27a (and other cluster partners). Data presented here also 
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suggest that there may exist a mechanism of androgen-mediated regulation that is specific to 
miR-27a, as miR-27a shows a greater androgen response than either miR-23a or miR-24-2. 
 
Discussion 
Previous studies suggested that downregulation of PHB by AR is a key step in cell cycle 
initiation in androgen-dependent cells, and PHB may thus play an important role in PCa (14). 
We found that PHB regulation by androgens is largely mediated by miRs, specifically miR-
27a. MiRs can act as oncogenes and tumour suppressors in a multitude of cancers. It is our 
hypothesis that oncomiRs can act by targetting important components of the androgen 
signalling pathway in PCa, and such oncomiRs may themselves be androgen regulated. This 
would result in a complex regulatory feedback loop that permits fine-tuning of AR activity. 
In gastric adenocarcinoma cells, inhibiting miR-27a was shown to inhibit growth, suggesting 
that it can act as an oncogene (23). We show here that miR-27a is subject to androgen 
regulation and demonstrate the direct consequences of miR-27a activity, and suppression 
thereof, on PHB expression, PCa cell growth and AR target gene expression. Further, we 
identify a novel mechanism for post-transcriptional modulation of miR biogenesis by AR. 
The PHB-3’UTR contains one predicted miR-27a binding site approximately 100bp 
3’ of the end of the coding region, which is highly conserved. This UTR conferred 
susceptibility for androgen-mediated downregulation to a luciferase reporter gene, suggesting 
that an androgen regulated factor associates with PHB-3’UTR to reduce its activity (Figure 
1). AR silencing/inhibition increased levels of PHB transcript, confirming the requirement for 
AR in regulation of PHB 3’UTR. A candidate intermediary factor was miR-27a, which we 
confirmed reduced PHB levels via specific binding to the 3’-UTR (Fig 2). The dominant 
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mechanism appears to be transcript degradation, rather than translational inhibition. 
Interestingly, PHB-3’UTR mutations have been reported in a number of breast cancer cell 
lines, including BT-20, SK-BR-3 and MCF7 (49), raising the possibility that mutations may 
occur in miR binding sites. Indeed, Sato et al demonstrated mutation of PHB in sporadic 
breast cancer (50) and Jakubowska et al have identified a C>T polymorphism in the 3’UTR 
of PHB as a breast cancer risk modifier in a Polish cohort carrying a BRCA1 mutation (51). In 
silico analysis performed on PHB 3’UTR mutations identified in breast cancer cell lines (49) 
has shown mutations in putative binding sites for several miRs. However, it is as yet 
unknown whether these miRs target PHB in vivo and whether they have roles in cancer; no 
mutations have yet been identified in the miR-27a binding sequence.  
Functional consequences of miR-27a manipulation in PCa cells include increased 
expression of androgen regulated genes, PSA and TMPRSS2, and increased androgen-
dependent growth. Conversely, the miR-27a ASO significantly reduced growth in the 
presence of androgen (Figure 3). In this context, it is noteworthy that Wee-1 and Myt-1 
(important regulators of cyclin B and cdc2, which, like PHB, have roles in cell cycle 
progression) both contain potential miR-27a complementary sites in their 3’UTRs and have 
been demonstrated to be bone fide targets (38). Further, it has been demonstrated in breast 
cancer that miR-27a targets ZBTB10, a repressor of the Sp family of transcription factors that 
have been implicated in carcinogenesis in breast cancer (38), and this may indirectly effect 
ERα levels (52). The observed increase in PARP cleavage upon miR-27a ASO transfection 
and decrease in anti-apoptotic survivin and anti-angiogenic VEGF and VEGFR1 (38) 
demonstrates the potential of miR-27a to function as an oncomiR in vivo by targeting several 
tumour suppressor proteins. An additional miR-27a target is the tumour suppressor FOXO1, 
which has important roles in cell cycle regulation and initiation of apoptosis (53). Similarly to 
PHB, it has been shown to be hormonally regulated and is downregulated in several cancers, 
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including endometrial carcinoma and ovarian cancer (54). These observations suggest that 
miR-27a targets proteins with important cell cycle regulatory roles, and, at least in PCa, 
androgen-mediated upregulation of miR-27a may be required to downregulate cell cycle 
inhibitors for cell cycle initiation and cell growth. This highlights the potential ‘oncomiR’ 
function of miR-27a.  
The multitude of potential miR-27a targets, several of which are also tumour 
suppressors, make it difficult to ascertain the relative contribution of miR-27a-targetting of a 
particular mRNA to observed phenotypic changes. An additional complicating factor is that 
miRs often act as “tuning agents”. In this model, miRs can function as rheostats to dampen 
protein levels to a more desirable level whilst still permitting the target protein to carry out 
essential functions in the cells. The combinatorial effects of low-level downregulation of 
multiple miR targets likely accounts for observed physiological effects following altered miR 
expression, rather than high efficiency targeting of a small number of mRNAs. Thus it cannot 
be discounted that the effects of miR-27a manipulation outlined here are due to low-level 
repression of several mRNA species. An argument for the key role of PHB is that we 
demonstrated that adding back PHB to cells with increased miR-27a resulted in inhibition of 
miR-27a-stimulated growth (Fig 3), indicating that here miR-27a is exerting its effects 
largely via PHB. However the suppression was not total. This could be a dosage effect but 
another likely explanation is that miR-27a suppression of other targets also contributes to the 
observed growth stimulation. 
We found that androgen regulation of miR-27a occurs via several mechanisms. Levels 
of the cluster primary transcript, primiR-23a27a24-2, initially increased with androgen 
treatment but soon after decreased, suggesting that androgen acts both to rapidly and directly 
increase primiR levels and also increase the rate of primiR or premiR processing thus 
depleting the primiR (Figures 5 and 6). This hypothesis is supported by the steady increase in 
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mature miR-27a following androgen addition. The mechanism of androgen regulation, 
therefore, appears not to be primarily stabilisation of the mature miR. As no evidence exists 
for independent primiR expression within the miR-23a27a24-2 cluster (unlike the miR-
23b27b24-1 cluster) and no internal poly(A) binding sites have been identified (43), and 
given the observation that both cluster partners, miR-23a and miR-24-2, demonstrate 
androgen regulation, we initially hypothesised that such regulation occurs at the level of 
transcription from the miR promoter and/or processing of the primary transcript. However, 
since the three miRs of the cluster show differing degrees of androgen regulation (Figure 4), 
it is possible that other unique regulation mechanisms exist, acting after primiR cleavage.  
When assessing miR cluster promoter activity we found that the proximal 700bp 
conferred androgen responsiveness to a reporter, and within this saw androgen-dependent AR 
association with the proximal –366 to –24 region (containing two predicted AREs) (Figure 
5). However, these moderate effects may not entirely explain the rapid accumulation of 
primary transcript 1h after MB treatment. AR may associate with additional regions or may 
require other factor(s) to associate efficiently with the miR promoter. Taken together, these 
data results indicate that transient association of AR with the miR-23a27a24-2 promoter 
results in a pulse of transcription of the miR cluster shortly after androgen treatment. 
However, primiR levels were increased following AR silencing (Fig 5D) or anti-androgen 
treatment (Fig 6E), an apparently paradoxical result. We showed using a Drosha cleavage 
reporter vector specific for the miR-23a27a24-2 cluster that androgens promote the cleavage 
of the primiR, which explains the increase in primiR upon AR silencing/inhibition, since 
blocking this processing would result in accumulation of the primiR. Thus it seems that AR 
also acts post-transcriptionally during miR biogenesis to increase miR-27a levels, supported 
by the fact that miR-27a, 23a and 24-2 accumulate in the absence of transcription following 
addition of androgens (Fig 6). While we have demonstrated that AR acts during Drosha-
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mediated primiR processing, the possibility that AR also acts to enhance Exportin 5-mediated 
primiR export, or to accelerate premiR processing by Dicer, cannot be entirely discounted. 
Work is ongoing to elucidate exactly where AR exerts its effects on miR-23a27a24-2 
processing and if this mechanism is unique to this cluster.  
This report proposes a novel mechanism for androgen regulation of oncomiR-27a and 
its growth suppressor target, PHB, in PCa, summarised in Figure 7. Androgen signalling 
results in a reduction in transcription of the PHB gene as shown previously (12). 
Additionally, androgen treatment leads to upregulation of miR-27a, through enhanced cluster 
transcription and increased primiR processing. MiR-27a then associates with the PHB-
3’UTR, resulting in transcript disruption and translational inhibition. These effects may be 
combinatorial and result in loss of PHB activity with a subsequent increase in AR activity 
and cell growth. As miR-27a ASO has been shown to increase PHB protein levels and reduce 
androgen-dependent PCa cell growth, miR-27a ASO may represent a novel therapeutic for 
the treatment of PCa. 
In conclusion, we have identified complex, multi-level regulation of PHB by AR, 
mediated by several interconnected pathways. Regulation occurs at the levels of transcription, 
translation and post-translation in a spatial as well as temporal manner. Such intricate 
regulation is vital for such a ubiquitous protein with many fundamental cellular roles and 
proven tumour suppressor capacity. The disregulation of PHB control through increased 
miR27a may promote carcinogenesis or maintenance of oncogenic phenotype in PCa.  
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Materials and Methods 
Mammalian Cell Culture 
Cells were maintained at 37˚C in 5% CO2. HeLa and Cos-1 cells were maintained in 
Dulbecco’s Modified Eagle’s Medium (DMEM) [Sigma], LNCaP, DuCaP, VCaP, C42, 
DU145, PC3 and PC3wtAR cells were maintained in RPMI-1640 (Sigma). All media were 
supplemented with 10% fetal bovine serum (FBS), 100U/ml penicillin, 100µg/ml 
streptomycin and 2mM L-glutamine (Sigma). 24-48h prior to ligand treatment, media were 
replaced with phenol red-free DMEM or RPMI-1640 as appropriate, supplemented with 5% 
charcoal-stripped FBS, 100U/ml penicillin, 100mg/ml streptomycin and 2mM L-glutamine. 
RWPE-1 cells were maintained in Keratinocyte-SFM (Life Technologies) supplemented with 
Epidermal Growth Factor 1-53 (5ng/ml) and Bovine Pituitary Extract (50µg/ml).  
Stably transfected LNCaP cell variants - LNCaP/AR-shRNA, LNCaP/scrambled-
shRNA (44) were maintained as above with 2.5µg/ml blasticidin, 1ug/ml puromycin. 
LNCaP/TR2/p2TetR/miR-27a and LNCaP/TR2/pcDNA4/TO-GFP-PHB were generated by 
stable transfection of LNCaP/TR2 cells (14) with p2TetR-miR-27a and pcDNA4/TO-GFP-
PHB respectively, and were maintained as above with 12µg/ml blasticidin, and 300µg/ml 
zeocin. 
Cell Lysis and Protein Extraction 
Cells were lysed and protein extracted as described (14). Lysates were stored at -20˚C. See 
Supp Exp Procedures. 
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Western Blot Analysis 
Proteins were resolved by 8-12% SDS-polyacrylamide gel electrophoresis and electroblotted 
to nitrocellulose membrane (Bio-Rad). After blocking (5% non-fat dried milk powder in 
0.05% Tween-20 in 1x TBS) for 40 minutes, membrane was incubated with mouse anti-AR 
mAb (Dako, 1/1000), mouse anti-PHB mAb (Neomarkers, 1/1000), or mouse anti-β-actin 
mAb (Abcam, 1/10,000) for 1h and visualised using goat anti-mouse IgG-HRP. Detection 
was by ECL reagents (Amersham).  
RNA Extraction and Non-Radioactive MiR Northern Blotting  
Total RNA was extracted from cells using Trizol reagent (Invitrogen) according to 
manufacturer’s protocol. Northern Blotting was performed on 5-20µg total RNA using 
double digoxygenin-labelled, LNA-modified probe (Exiqon) complementary to the sequence 
of mature miR-27a, as described previously (55) with the following amendments: RNA was 
electrotransferred to positive nylon membrane (Roche) at 300mA for 40 minutes and 
hybridisation was performed at 37˚C using UltraHyb hybridisation buffer (Ambion), 
followed by washing in 2xSSC, 0.1% SDS and then 0.1xSSC, 0.1% SDS at 37˚C. Ethidium 
bromide staining of rRNAs was used as a loading control. Blots were analysed by addition of 
CDP-Star (Roche) and exposure of film to membrane or by membrane staining with 
BCIP/NBT (Vector Laboratories). Quantification was performed using Image J software.  
Semi-Quantitative RT-PCR 
500ng total RNA was reverse transcribed using oligo d(T) primers and the qScript Reverse 
Transcription kit (PrimerDesign). PCR was performed using 12.5µl TaqReddy Mix 
(Abgene), 0-2µg cDNA and 25pmol forward and reverse primers per reaction and made to 
25µl with ddH2O. Primer sequences for amplification of PHB 3’UTR, AR, and L19 are 
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shown (Table 1, Supp Exp Procedures). Samples were thermocycled as follows: 94˚C–4min, 
30-40 cycles of (94˚C-30s, 52-65˚C–30-60s, 72˚C–30-120s), 72˚C–10min. PCR products 
were analysed by agarose gel electrophoresis. 
MiR and mRNA Quantification by Quantitative Real-Time RT-PCR 
Mature miR expression was quantified by quantitative real-time RT-PCR using the TaqMan 
microRNA assay for hsa-miR-27a, hsa-miR-23a, hsa-miR-24, hsa-U18 and hsa-miR-182 
(Applied Biosystems) and TaqMan Universal PCR Master Mix (Applied Biosystems) 
according to the manufacturer’s protocol. 5-10ng total RNA was reverse transcribed per 
reaction. PCR was performed using 1.5µl of the obtained cDNA in an ABI 900HT Real-Time 
PCR System under the 9600 Emulation mode. Cycling conditions were: 95˚C–10mins, 40 
cycles of (95˚C–15s, 60˚C–60s). For detection of PHB, primiRs, AR and AR target genes, 
cDNA was prepared from 500ng total RNA using Precision qScript Reverse Transcription kit 
(PrimerDesign) and oligo d(T) primer. cDNAs were amplified using 2x Fast SYBR Green 
Master Mix (Applied Biosystems) and 250nM forward and reverse primers (Table 2, Supp 
Exp Procedures). All data was analysed using the ΔΔCt method, with U18 and L19 as 
endogenous references for miR and mRNA levels respectively, using ethanol-treated samples 
as calibrators. 
Oligonucleotide and Plasmid Transfection 
MiR-27a anti-sense (ASO), scrambled ASO and miR-27a mimic were synthesised by MWG 
Eurofins (see Table 3, Supp Exp Procedures). Transfection of miR-27a/ASO was performed 
using Dharmafect 2 (Dharmacon) on LNCaP cells at 50% confluency. Transfection 
complexes were added to cells at a final concentration of 0-500nM. After 24h, RNA was 
extracted. Whole cell lysates were prepared 48h after transfection. For transfection of 
LNCaP/GFP-PHB with miR-27a for SRB assays, miR-27a and negative control mimics were 
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purchased from Dharmacon. Mimic transfection was performed using Lipofectamine 
RNAiMAX (Invitrogen) to give a final mimic concentration of 100nM. Lipofectamine LTX 
(Invitrogen) was used for transfection of LNCaP/miR-27a cells with pcDNA4/TO-GFP-PHB 
to yield final plasmid concentrations of 0.3 or 1.5ng/µl. 
PHB-3’UTR Analysis 
The 200bp SV40 promoter mRNA sequence was inserted into the MCS of pGL4.18 vector 
(Promega) using BglII and HindIII restriction sites to generate pSV40-GL4.18. A 900bp 
DNA fragment corresponding to the PHB-3’UTR was then inserted 3’ of the luc2 gene using 
XbaI and SalI to generate the pSV40-GL4.18-PHB-3’UTR vector. Subsequently, miR-27a 
binding site residues of the 3’UTR were mutated using the QuikChange Lightning Site-
Directed Mutagenesis Kit (Stratagene) to produce pSV40-GL4.18-PHB-3’UTR mutant (Fig 
2A). pSV40-GL4.18-PHB-3’UTR or the mutant derivative vector (0-8µg) were 
contransfected with pSVAR and pdmLacZ into HeLa cells using the calcium phosphate 
method (56). For inhibition of miR-27a activity, miR-27a anti-sense (0-10µg) was transfected 
into HeLa cells alongside expression and reporter vectors. 24h post-transfection, cells were 
treated with MB or vehicle (EtOH) and harvested after a further 24h.  
PrimiR-23a27a24-2-Specific Drosha Cleavage Activity Assay 
 
The 602bp CMV promoter mRNA sequence was inserted into the MCS of pGL4.18 vector 
(Promega) using NheI and KpnI restriction sites to generate pCMV-GL4.18. The 390bp miR-
23a27a24-2 genomic sequence was then inserted 5’ of the luc2p gene and 3’ of the CMV 
promoter in the pCMV-GL4.18 using BglII and HindIII restriction sites to generate the 
pCMV-primiR-23a27a24-2-GL4.18. This vector was cotransfected into Cos-1 cells alongside 
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pSVAR and pdmLacZ using the calcium phosphate method (56). 24h post-transfection, cells 
were treated with MB ± Bic, or vehicle (EtOH) and harvested after a further 24h. 
Reporter Assays  
Luciferase assays were performed using the Luclite assay (Packard, USA) and activity 
normalised for transfection efficiency using the Galacton kit (Tropix) as previously described 
(12). See Supp Exp Procedures.  
Chromatin Immunoprecipitations (ChIP) 
Cells grown in starvation medium for 3 days were treated with 10nM MB for 0-2 hours. ChIP 
was performed on formaldehyde cross-linked cell samples as described (57). The presence of 
miR-23a27a24-2 promoter in immunoprecipitates was quantified by qRT-PCR using 5µl 
DNA and Fast SYBR Green qPCR mix (Applied Biosystems). Primers shown in Table 4, 
Supp Exp Procedures.  
Sulphorhodamine B (SRB) Assay 
Cell number was estimated using the SRB assay as previously described (13). See Supp Exp 
Procedures. 
Statistical Analyses 
 
Normally distributed continuous variables were assessed by student’s t test. Strength of 
correlation between two normally distributed continuous variables was assessed by Pearson’s 
correlation coefficient (r). P≤0.05 was interpreted to denote statistical significance. 
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Figure Legends 
Figure 1. Androgen signalling downregulates PHB 3’UTR activity. (A) Luciferase activity in 
extracts of HeLa cells cotransfected with wild-type AR expression construct pSVAR and 1µg 
SV40-GL4-PHB3’UTR prior to 24h treatment with 10nM Mibolerone (MB) vehicle (EtOH). 
Luciferase was normalised for transfection efficiency (β-galactosidase activity) and mean ± 
SEM of three independent experiments is shown. (B) RT-PCR analysis of PHB-3’UTR, AR 
and L19 levels in LNCaP/TR2/Scram and LNCaP/TR2/AR shRNA cells treated with 
doxycycline (dox) for 48h to induce expression of scrambled AR shRNA or AR shRNA. 
Western blotting was performed on protein lysates to confirm silencing of AR, for which β-
actin was used as a loading control. (C) qRT-PCR analysis of PHB coding region and PHB-
3’UTR from PC3wtAR cells treated with MB (10nM) for 24h prior to RNA extraction. 
Reverse transcription and qPCR were performed using primers as indicated. Columns: mean 
relative gene expression from three independent experiments ± SEM. (D) Semi-quantitative 
RT-PCR analysis of LNCaP cells treated with MB (1nM) ± bicalutamide (Bic) (10µM) for 
24h. P ≤ 0.05 , ** P ≤ 0.005. See also Fig S1. 
Figure 2. PHB is a target of MiR-27a Activity in Prostate Cancer Cells. (A) Schematic 
representation of miR-27a binding to PHB 3’UTR and PHB 3’UTR mutant reporter 
constructs used in (B). See also Fig S2. (B) Luciferase reporter activity in extracts from HeLa 
cells transfected with wild-type AR expression vector pSVAR, 1µg SV40-GL4-Wt/Mutant 
PHB-3’UTR and 0-5µg p2TetR/miR-27a. Data shown represent mean ± SEM of three 
independent experiments performed in duplicate. Luciferase activity is normalised for 
transfection efficiency by cotransfection of β-galactosidase expression vector and data is 
presented relative to activity of WT reporter in the absence of exogenous miR-7a. (C) 
Western blot analysis of LNCaP/TR2/p2TetR-miR-27a cells treated with 0.0-1.0µM dox for 
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24h. Image quantification performed using ImageJ software. (D) Analysis of relationship 
between PHB protein levels and miR-27a levels in a panel of prostate cancer cells lines. PHB 
protein levels were assayed by Western blot and miR-27a levels by qRT-PCR.  Data was 
normalised using β-Actin protein level and U18 expression respectively, and represents mean 
± SEM of 3 independent experiments. Pearson correlation coefficient (r) was calculated to 
assess correlation between PHB protein levels and miR-27a expression. (E) qRT-PCR 
analysis of entire PHB transcript levels from LNCaP/TR2/p2TetR-miR-27a cells treated with 
dox (0-0.2µM) for 24h to induce miR-27a expression. Data was normalised using L19 
expression and represents mean ± SEM of 3 independent experiments performed in triplicate. 
(F) LNCaP cells were transfected with oligos [scrambled (0.2µM), miR-27a (0.2µM), or 
miR-27a anti-sense (0-1.0µM)]. After 72h, cells were harvested and extracts immunoblotted 
for β-Actin and PHB protein. Quantification was performed using ImageJ software. Graph 
shows mean ± SEM of three independent experiments and a representative blot is shown 
(insert). (G) Luciferase reporter activity from HeLa cells transfected with WT SV40-GL4-
PHB-3’UTR as for Fig 2B, with the addition of 0-10µg miR-27a ASO. After 48h, cells were 
harvested, data normalised and presented as for Fig 2B. (H) Semi-quantitative RT-PCR 
analysis of PHB-3’UTR, AR and L19 levels from LNCaP cells transfected with 0.5µg ASO 
or scrambled oligo. L19 was used as a control for loading and quantification performed using 
Image J software. Numbers represent relative PHB-3’UTR expression ± SEM. * P ≤ 0.05, ** 
P ≤ 0.005. See also Fig S2. 
Figure 3: MiR-27a manipulation alters expression of AR target genes and prostate 
cancer cell growth. (A) qRT-PCR analysis of PSA and TMPRSS2 mRNA levels from 
LNCaP/TR2/p2TetR-miR-27a cells treated with dox (0-0.2µM) for 24h. L19 expression was 
used for normalisation of mRNA levels. Columns: mean relative mRNA levels from two 
independent experiments performed in triplicate ± SEM. * P ≤ 0.05, ** P ≤ 0.05. (B,C) 
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Sulphorhodamine B growth assays of LNCaP/TR2/p2TetR-miR-27a cells treated with 10nM 
MB ± 1µM dox to induce miR-27a expression (B) or with additional transfection of GFP-
PHB (pcDNA4/TO-GFP-PHB) or empty pcDNA4/TO using Lipofectamine LTX (C). See 
also Fig S3. (D) Sulphorhodamine B growth assays of LNCaP/TR2/pcDNA4/TO-GFP-PHB 
cells treated with 10nM MB ± 1µM dox to induce GFP-PHB expression, with additional 
transfection of miR-27a mimic or negative control oligo at a final concentration of 200nM. 
(E) Sulphorhodamine B growth assays of LNCaP cells transfected with miR-27a ASO or a 
scrambled miR-27a ASO at a final concentration of 50nM ± 10nM MB. (B-E) SRB assays 
were performed at 0, 2, 4 and 6 days post treatment (B,E) or at 0, 1, 3, 5 and 7 days post 
transfection/treatment (C,D). Points: mean relative absorbance at 492nm, where absorbance 
at day 0 was set at 1 for all treatment conditions (B,E), absorbance at day 5 in the presence of 
MB and absence of PHB was set at 1 (C), or absorbance at day 5 in the absence of any 
treatment was set at 1 (D). Points represent mean of three independent experiments 
performed in six replicate wells per experiment ± SEM. * P ≤ 0.05.  
Figure 4: The MiR-23a27a24-2 Cluster is Regulated by Androgen in Prostate Cancer 
Cells. (A) qRT-PCR analysis of miR-27a levels from LNCaP cells treated with MB (10nM) 
or an equal volume of ethanol for 0-24h. RNA was reverse transcribed using miR-specific 
primers, followed by qPCR for miR-27a. U18 was used as a normalisation gene. (B) Diagram 
illustrating structure of the human miR-23a27a24-2 cluster. (C) qRT-PCR analysis of miR-
23a27a24-2 cluster members from LNCaP cells treated with MB (1 or 10nM) ± Bic (1 or 
10µM) or an equal volume of ethanol for 24h. MiR-specific primers were used for reverse 
transcription followed by qPCR for mature miR-27a, miR-23a and miR-24 using U18 
expression as a normalisation control. Columns: mean relative miR expression for three 
independent experiments performed in triplicate ± SEM. * P ≤ 0.05, # P ≤ 0.001 relative to 
0h/untreated samples. (D) Northern blot analysis of miR-27a levels from 10µg total RNA 
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extracted from LNCaP cells treated with MB (1 or 10nM) ± Bic (1 or 10µM) or an equal 
volume of ethanol for 24h. Ethidium bromide staining was performed as a control for equal 
loading and ImageJ software was used for quantification.  
Figure 5: AR Associates with the Proximal Mir23a27a24-2 Promoter in Prostate Cancer 
Cells in Response to Androgen, Transiently Increasing Primary Transcript Levels and 
Enhancing Drosha-Mediated PrimiR Cleavage (A) Luciferase activity assay of Cos-1 cells 
transfected with 100ng AR expression vector pSVAR and 1µg of either proximal or distal 
miR-23a27a24-2 promoter reporter vector for 24h, followed by 24h treatment with MB 
(10nM) or an equal volume of ethanol. β-galactosidase activity was used as a control for cell 
number. Data represent mean relative luciferase activity for three independent experiments 
with duplicate analyses of each RNA sample ± SEM. (B) ChIP analysis of AR recruitment to 
the miR-23a27a24-2 cluster promoter in LNCaP cells treated with MB (10nM) for 0-2h. The 
purified DNA fraction was probed for presence of proximal miR-23a27a24-2 promoter by 
qPCR. AR relative enrichment is displayed as a percentage of the input value. Data represent 
mean AR % pull down relative to IgG for three independent experiments ± SEM. * P ≤ 0.05. 
See also Fig S4. (C) qRT-PCR analysis of primiR-23a27a24-2 from LNCaP cells treated with 
MB (10nM) or an equal volume of ethanol for 0-24h. L19 was used as a normalisation gene. 
Data represent mean of three independent experiments ± SEM. * P ≤ 0.05, ** P ≤ 0.001 
relative to 0h/untreated samples. See also Fig S5. (D) qRT-PCR analysis of primiR-
23a27a24-2 and AR levels from LNCaP/Scram and LNCaP/AR shRNA cells treated with dox 
for 48h to induce expression of scrambled AR shRNA or AR shRNA. L19 expression was 
used as a normalisation control. (E) Luciferase activity in extracts of Cos-1 cells 
cotransfected with wild-type AR expression construct pSVAR and 100ng CMV-PrimiR-
23a27a24-2-GL4 (primiR-23a27a24-2-specific Drosha cleavage reporter) prior to 24h 
treatment with 1-10nM Mibolerone (MB) ± 1-10µM Bicalutamide (Bic) or vehicle (EtOH). 
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Luciferase was normalised for transfection efficiency (β-galactosidase activity) and mean ± 
SEM of three independent experiments is shown. Upper panel: diagram illustrating structure 
of the primiR-23a27a24-2-specific Drosha cleavage reporter. See also See also Fig S6. 
Figure 6: Androgen Regulation of the PrimiR-23a27a24-2 Cluster Occurs Post-
Transcriptionally. (A) qRT-PCR analysis of primiR-23a27a24-2 and mature miR-27a levels 
(i,ii), or L19 levels (iii) from LNCaP cells grown in stripped medium and treated with 
Actinomycin D (1µM) and MB (1nM), ethanol, or ethanol or MB (1nM) for 0-48h. Reverse 
transcription was performed using oligo d(T) primers (primiR-23a27a24-2 and L19) or miR-
specific primers (miR-27a). (B,C,D) qRT-PCR analysis of miR-23a (B), miR-24 (C) and 
miR-182 (D) from LNCaP cells grown in stripped medium and treated with Actinomycin D 
(1µM) ± MB (1nM) for 0-48h. Reverse transcription was performed using miR-specific 
primers. (A-D) Data represents mean relative gene expression for three independent 
experiments ± SEM. See also Fig S7. (E,F) qRT-PCR analysis of primiR-23a27a24-2 and 
miR-27a levels from PC3wtAR cells treated with 10nM MB ± 10µM Bic for 24h. L19 and 
U18 expression levels were used as normalisation controls for primiR-23a27a24-2 and miR-
27a levels respectively. Data represent mean ± SEM for three independent experiments. (G) 
qRT-PCR analysis of miR-27a levels from LNCaP/TR2/scram and LNCaP/TR2/AR shRNA 
cells grown in stripped medium and treated with MB (10nM) ± dox for 48h. U18 expression 
was used as a normalisation control and data represent mean relative miR-27a expression for 
three independent experiments ± SEM. * P ≤ 0.05, ** P ≤ 0.001. 
Figure 7: Model for Androgen and MiR-27a Control of PHB Protein Expression. (1) AR 
downregulates PHB at the promoter. (2) AR transiently associates with AREs in the miR-
23a-27a24-2 promoter, increasing levels of the primary transcript (3) AR enhances primiR to 
premiR processing (4) In the absence of AR signalling, little primiR is converted to premiR 
and cellular levels of miR-27a are low (5) PremiR-27a is converted to mature miR-27a by 
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Dicer in the cytoplasm (6) miR-27a inhibits PHB translation/degrades PHB mRNA. (7) Low 
PHB leads to increased cell growth. (8) Adding ASO inhibits miR-27a, leading to... (9) 
Increased cellular levels of PHB. (10) Increased PHB levels inhibit AR activity, which results 
in...(11) No repression of PHB by AR and (12) No repression of PHB by miR-27a, due to 
presence of ASO. This results in (13) Further increase in PHB protein levels and ultimately 
(14) PHB-induced cell cycle arrest. 
 
40 
	  
Abbreviations 
ActD   Actinomycin D 
AR   Androgen Receptor 
ARE   Androgen response element 
ASO   Anti-sense oligonucleotide 
Bic   Bicalutamide 
Dox   Doxycycline 
MB   Mibolerone 
miR   MicroRNA 
miR-27a  Homo sapiens microRNA-27a 
OncomiR  Oncogenic microRNA 
PCa   Prostate cancer 
PHB   Prohibitin 
PSA   Prostate-specific antigen 
shRNA  short hairpin RNA 
PHB For!
 PHB rev! UTR rev 1!
A! B!
D!
0!
5!
10!
15!
20!
25!
30!
0! 1! 2! 4! 8!R
ela
tiv
e 
PH
B 
3ʼU
TR
 R
ep
or
te
r A
cti
vit
y!
PHB 3'UTR Reporter Vector (µg)!
EtOH!
10nM Mib! +!-!
LNCaP/Scram! LNCaP/AR siRNA!
L19!
AR!
PHB-3ʼU
TR!
Dox:!
AR!
β-Actin!
+!-!
RT-
PCR!
WB!
0!
0.2!
0.4!
0.6!
0.8!
1!
1.2!
1.4!
EtOH! MB! EtOH! MB!
PHB Rev! UTR Rev 1!
Re
lat
ive
 E
xp
re
ss
ion
!
RT Reverse Primer!
PC3WTAR!
PHB! PHB-3ʼUTR!Mir27a BS!
PHB-3ʼUTR!
L19!
AR!
Fu
ll! _!
M
B!
M
B 
+ 
Bi
c!
LNCaP!
Stripped!
C!
* **	  
Figure 1!
*	  
	  *	  
MB!
0!
0.2!
0.4!
0.6!
0.8!
1!
1.2!
0! 0.1! 0.2!
PH
B 
3'U
TR
/L
19
 R
ela
tiv
e 
Ex
pr
es
sio
n!
Dox (µM)!
LNCaP/MiR-27a!
0!
0.5!
1!
1.5!
2!
2.5!
3!
3.5!
0! 0.5! 5! 0! 0.5! 5!
PHB 3'UTR! PHB 3'UTR Mutant!Re
lat
ive
 P
HB
 3
ʼU
TR
 R
ep
or
te
r A
cti
vit
y!
Mir27a (µg)!
cgccuugaaUCGGUGACACUu	  
CUCCCACCCCAGAAAUCACUGUGAAAUUUCAUGA 
CUCCCACCCCAGAAAUCAGUGUGCAAUUUCAUGA 
76 (5ʼ)! 109 (3ʼ)!
WT PHB 
3ʼUTR!
PHB 3ʼUTR 
Mutant!
5ʼ!3ʼ!
:	  
MiR-27a!
Seed region!
A! B!
E!
C!
*	  
*	  
0.0! 0.1! 0.2! 1.0!Dox (µM):!
LNCaP/MiR-27a!
PHB!
β-Actin!
WB!
1.00! 0.10! 0.16! 0.32!
Relative 
Expression:!
	  	  	  **	  
MiR-2
7a 
(µg): 
HeLa!
Figure 2!
G!
0!
0.2!
0.4!
0.6!
0.8!
1!
1.2!
1.4!
1.6!
1.8!
2!
2.2!
2.4!
2.6!
0.0! 0.5! 1.0! 2.0! 5.0! 10.0!
Re
lat
ive
 P
HB
 3
'U
TR
 R
ep
or
te
r A
cti
vit
y!
MiR-27a ASO (µg)!
0.5ug p2TetR!
0.5ug p2TetR-miR-27a!
*
*
H!
	  
**	  
PHB-3ʼUTR!
L19!
Un
T!
AS
O!
Sc
ra
m
!
LNCaP!
1.00 ± 
0.19!
2.06 ± 
0.08!
1.07 ± 
0.26!
Relative PHB 
3ʼUTR Levels!
0!
0.2!
0.4!
0.6!
0.8!
1!
1.2!
1.4!
1.6!
1.8!
2!
2.2!
2.4!
2.6!
2.8!
3!
3.2!
Scram	   Mir27a	  5	   ASO	  1	  Mir27a	  2	   ASO	  2	  Mir27a	  2	   ASO	  5	  Mir27a	  2	   ASO	  5	  
PH
B/
β-
Ac
tin
 R
ela
tiv
e 
Ex
pr
es
sio
n!
F!
PHB!
β-Actin!
Sc
ra
m
!
M
iR
-2
7a
!
ASO!
MiR-27a!
AS
O!
WB!
*
*
*
*
Sc
ra
m
!
M
iR
-2
7a
!
AS
O!
ASO!
MiR-27a!
D
r = -0.881!
0!
0.5!
1!
1.5!
2!
2.5!
0! 0.2! 0.4! 0.6! 0.8! 1! 1.2! 1.4! 1.6!
Re
la
tiv
e 
PH
B 
Pr
ot
ei
n 
Le
ve
l!
Relative MiR-27a Level!
RWPE1!
LNCaP!
DuCaP!
VCaP!
C42!
DU145!
PC3!
0!
0.5!
1!
1.5!
2!
2.5!
3!
3.5!
4!
-! +! -! +! -! +! -! +!
-! -! +! +! -! -! +! +!
-! -! -! -! +! +! +! +!
M
ea
n 
Re
la
tiv
e A
bs
or
ba
nc
e!
LNCaP/GFP-PHB !
0!
0.5!
1!
1.5!
2!
2.5!
3!
3.5!
4!
0.0! 0.1! 0.2! 0.0! 0.1! 0.2!
PSA! TMPRSS2!
Re
lat
ive
 m
RN
A 
Ex
pr
es
sio
n!
Doxycycline (µM)!
LNCaP/MiR-27a!
A B
0.8!
1!
1.2!
1.4!
1.6!
1.8!
2!
0! 2! 4! 6!
Re
lat
ive
 G
ro
wt
h!
Time (d)!
LNCaP/MiR-27a!
Untreated 
1µM doxycycline 
10nM mibolerone 
1µM doxycycline + 
10nM mibolerone 
*	  
UnT!
Dox!
MB!
Dox + 
MB!
0!
0.5!
1!
1.5!
2!
2.5!
3!
3.5!
0! 2! 4! 6!
Re
lat
ive
 G
ro
wt
h!
Time (d)!
LNCaP/MAR4!
UnT!
Scram!
Scram + 
Mib!
ASO!
ASO + 
Mib!
*	  
C
*
*
**	  
**	  
Figure 3 
MB:!
GFP-PHB:!
*!
miR-27a:!
0 
0.2 
0.4 
0.6 
0.8 
1 
1.2 
- + ++ - + ++ 
- - - + + + 
M
ea
n 
R
el
at
iv
e 
A
bs
or
ba
nc
e 
at
 4
92
nm
 
LNCaP/miR-27a + MB!
* 
* 
n.s.!
PHB: 
MiR-27a: 
*!
ED
n.s.	  
1.00!
1.05!
1.10!
1.15!
1.20!
1.25!
1.30!
1.35!
1.40!
1.45!
-! +!
M
ea
n A
bs
or
ba
nc
e 
at
 4
92
nm
!
miR-27a!
* 
0!
1!
2!
3!
4!
5!
6!
7!
-! 1! 10! 1! 1!
-! -! -! 1! 10!
Re
lat
ive
 E
xp
re
ss
ion
!
LNCaP! MiR-27a!
MiR-23a!
MiR-24!
#	  
#	  
#	  
*	   *	  
*	  
#	  
0!
0.5!
1!
1.5!
2!
2.5!
3!
- + ++ + + 
- - - + ++ 
M
iR
-2
7a
/E
tB
r R
ela
tiv
e 
Ex
pr
es
sio
n!
PC3wtAR!
0.0!
0.5!
1.0!
1.5!
2.0!
2.5!
3.0!
3.5!
0! 1! 2! 4! 8! 16! 24! 24 
EtOH!
M
iR
-2
7a
/U
18
 R
ela
tiv
e 
Ex
pr
es
sio
n!
Time (h)!
LNCaP!
*	   *	  
*	  
**	  
MB (nM):!    -              1            10             1             1!
Bic (µM):!         -              -              -              1            10!
MiR-27a!
EtBr!
Et
OH
! MB! Bic!
MB!
 MB (nM):!
Bic (µM):!
A B
C
0 36!124!-410!-633!-530! 1752! 1757!
Poly A 
Signal!
TSS!
Promoter Region!
GC Rich 
Region!
23a! 27a! 24-2!
2159bp!
D
* 
10nM MB 
Figure 4!
0!
0.5!
1!
1.5!
2!
2.5!
3!
3.5!
0! 30! 60! 120! 0! 30! 60! 120!
AR! Rb IgG!
AR
 %
 P
ull
 D
ow
n!
Time (min)!
ChIP – MiR-23a27a24-2 Promoter!
0!
1!
2!
3!
4!
5!
6!
7!
8!
9!
-! +! -! +! -! +!
GL4! -726 to -23! -2982 to -1942!
Re
lat
ive
 L
uc
ife
ra
se
 A
cti
vit
y!
Cos-1: MiR-23a27a24-2 Promoter!A B
*
MB :!
*
MiR-23a27a24-2 Promoter Region!
Figure 5!
0!
1!
2!
3!
4!
5!
6!
7!
8!
9!
0! 1! 2! 4! 8! 16! 24! 24E!
Pr
im
iR
-2
3a
27
a2
4-
2/
L1
9 
Re
lat
ive
 E
xp
re
ss
ion
!
Time (h)!
PrimiR-23a27a24-2!
C D
**	  
**	  
**	  
0!
0.5!
1!
1.5!
2!
2.5!
3!
3.5!
MB! MB Dox! MB! MB Dox!
Scram! AR KO!
Pr
im
iR
-2
3a
27
a2
4-
2/
L1
9 
Re
lat
ive
 E
xp
re
ss
ion
!
PrimiR-23a27a24-2! *!
0 
0.2 
0.4 
0.6 
0.8 
1 
1.2 
- 1 10 1 1 - 
- - - 1 10 10 
Pr
im
iR
-2
3a
27
a2
4-
2 
C
le
av
ag
e 
R
ep
or
te
r 
A
ct
iv
ity
 
MB (nM): 
Bic (µM): 
* *
CMV! PrimiR-23a27a24-2! Luc2p!
E
0!
0.5!
1!
1.5!
2!
2.5!
-! -! +! +!
-! +! +! -!
M
iR
-2
7a
/U
18
 R
ela
tiv
e 
Ex
pr
es
sio
n!
MiR-27a!
0!
0.5!
1!
1.5!
2!
2.5!
-! +! +! -!
-! -! +! +!
Pr
im
iR
-2
3a
27
a2
4-
2/
L1
9 
Re
lat
ive
 E
xp
re
ss
ion
! PrimiR-23a27a24-2!
0!
1!
2!
3!
4!
5!
6!
7!
8!
0! 6! 24! 48!R
ela
tiv
e 
Pr
im
iR
/M
at
ur
em
iR
 E
xp
re
ss
ion
!
Actinomycin D (h)!
PrimiR-23a27a24-2!
Mature miR-27a!
**	  
**	  
**	  
*	  
*
A i!
MB (h):!
0!
0.2!
0.4!
0.6!
0.8!
1!
1.2!
1.4!
1.6!
0! 6! 24! 48!R
ela
tiv
e 
Pr
im
iR
/M
at
ur
em
iR
 E
xp
re
ss
ion
!
Actinomycin D (h)!
PrimiR-23a27a24-2!
Mature miR-27a!
MB EtOH 
0!
0.2!
0.4!
0.6!
0.8!
1!
1.2!
1.4!
1.6!
1.8!
0! 6! 24! 48!
L1
9 
m
RN
A 
Ex
pr
es
sio
n!
Actinomycin D (h)!
L19 EtOH 
MB 
ii! iii!
EtOH (h): EtOH/MB (h):!
GE
0!
0.5!
1!
1.5!
2!
2.5!
3!
3.5!
MB! Dox/MB! MB! Dox/MB!
LNCaP/Scram! LNCaP/AR 
siRNA!
M
iR
-2
7a
/U
18
 R
ela
tiv
e 
Ex
pr
es
sio
n!
MiR-27a! *	  
Figure 6!
*
*
0!
0.2!
0.4!
0.6!
0.8!
1!
1.2!
1.4!
1.6!
1.8!
2!
0! 6! 24! 48!
M
iR
-1
82
/U
18
 R
ela
tiv
e 
Ex
pr
es
sio
n!
Actinomycin D (h)!
EtOH!
MB!
MiR-182 
0!
0.5!
1!
1.5!
2!
2.5!
3!
3.5!
4!
0! 6! 24! 48!
M
iR
-2
4/
U1
8 
Re
lat
ive
 E
xp
re
ss
ion
!
Actinomycin D (h)!
EtOH 
MB 
MiR-24 
0!
0.5!
1!
1.5!
2!
2.5!
3!
3.5!
4!
4.5!
0 6 24 48 
M
iR
-2
3a
/U
18
 R
ela
tiv
e 
Ex
pr
es
sio
n!
Actinomycin D (h) 
EtOH!
MB!
MiR-23a *	  
*	  
B C D
*! **!
*! *!*!
MB:!
Bic:!
MB:!
Bic:!
F
Figure 7 
PHB! PHB!
PHB! PHB!
PHB!
miR-27a!
ASO!
10!
1!
Promoter! 23a ! 27a ! 24-2 !
23a! 27a! 24-2!
AAAA!
- AR!
Pre-
miR-27a!
miR-27a!
Pri-
miR-23a27a
24-2!
miR-27a!
2!
3!
4!
5!
6,12!
7!
9,13!
 AR!
A!
AR!
A!
PHB!
Promoter! PHB! 3ʼUTR! Promoter! PHB! 3ʼUTR!
AR!
A!
AR!
A!
8!
11!
14!
Supplemental Experimental Procedures 
 
Cell Lysis and Protein Extraction 
Cells were washed twice with PBS and pelleted by centrifugation at 1000xg for 4 minutes. 
Pellets were resuspended in cell lysis buffer (100mM NaCl, 0.5% NP40, 50mM Tris-HCl (pH 
8.0), 0.2mM PMSF, 5µl/ml proteinase inhibitor cocktail and 10µl/ml phosphatise inhibitor 
cocktails 1 and 2 [Sigma]). Lysates were incubate on ice for 15min and centrifuged at 
13,000xg for 7 minutes to remove cell debris. Supernatant (lysate) was removed and stored at 
-20˚C. 
Luciferase Assay  
Luciferase assays were perfomed using the Luclite assay (Packard, USA). Cells frozen in 
reporter lysis buffer were thawed on ice and 20µl of the lysate was mixed with 20µl of 2x 
luclite substrate (PerkinElmer) in a 96-well Optiplate (Packard, USA). Plates were incubated 
at room temperature in the dark for 15 minutes. Luminescence (counts per second) was 
measured using a VICTOR Light luminescence counter (PerkinElmer). Luminescence values 
were normalised to β-galactosidase activity (see below). 
β-Galactosidase Assay  
Assays were performed using the β-galactosidase assay kit (Tropix, UK). Galacton substrate 
was diluted 100-fold in Galactolight reaction buffer diluent. 5µl of cell lysate was mixed with 
50µl of galacton substrate in a 96-well Optiplate. Each plate was incubated for 60 minutes at 
room temperature in the dark after which 75µl of Accelerator II (Tropix) was added to each 
well. β-galactosidase activity was measured using the VICTOR Light luminescence counter 
as described above and used to correct for transfection efficiency. 
Sulphorhodamine B (SRB) Assay 
Cells were fixed in 100µl (96-well) or 500µl (24-well) 40% trichloroacetic acid (TCA) added 
directly to cell medium for 1 hour. Plates were washed with water and air-dried. Cells were 
stained using SRB (0.4%w/v in 1% acetic acid) and incubated for 1 hour. Plates were then 
washed x5 in 1% acetic acid and air-dried. SRB was solubilised in 100µl (96-well) or 400µl 
(24-well) 10mM Tris-HCl pH8.0 and absorbance was read at 492nm. 
 
  
Supplemental Tables 
 
Table 1: Primer Sequences for Semi-Quantitative RT-PCR  
 
Amplification 
Product 
Primers Primer Sequences 
L19 
L19 F 5’ GCAGCCGGCGCAAA 3’ 
L19 R 5’ GCGGAAGGGTACAGCCAAT 3’ 
PHB 
Prohib F 5’ GGCTGAGCAACAGAAAAAGG 3’ 
Prohib R 5’ GCTGGCAGGTAGGTGATGTT 3’ 
PrimiR-23a27a24-2 
Pri23a27a24-2 F 5’-CGCCCGGTGCCCCCCTCACCCCTGTGCCAC-3’ 
Pri23a27a24-2R 5’-CCCTGTTCCTGCTGAACTGAGCCAGTGTAC-3’ 
AR 
AR F (E) 5’-CTGCCCCATCCACGTTGTCCCTGCT-3’ 
AR R (F) 5’GACTCAGATGCTCCAACGCCTCCAC-3’ 
 
Primers Sequences used for Semi-Quantitative RT-PCR. This table relates to Experimental Procedures: Semi Quantitative RT-PCR and 
Figs 1 and 2.  
  
Table 2: Primer Sequences for SYBR Green qRT-PCR  
 
Amplification 
Product 
Primers Primer Sequences 
L19 
L19 F 5’ GCAGCCGGCGCAAA 3’ 
L19 R 5’ GCGGAAGGGTACAGCCAAT 3’ 
PHB Coding Region 
Prohib F 5’ GGCTGAGCAACAGAAAAAGG 3’ 
Prohib R 5’ GCTGGCAGGTAGGTGATGTT 3’ 
PHB 3’UTR Full 
UTR For 5’-TAATCTAGAGGGCCCACCCTGCCTGCACCTCCGCGGG-3’ 
UTR rev long NRS 5’-GGAAGGTCTGGGTGTCATTTATTGACAGCAGTTT-3’ 
PrimiR-23a27a24-2 
Pri23a27a24-2 F 5’-CGCCCGGTGCCCCCCTCACCCCTGTGCCAC-3’ 
Pri23a27a24-2R 5’-CCCTGTTCCTGCTGAACTGAGCCAGTGTAC-3’ 
AR 
AR F (E) 5’-CTGCCCCATCCACGTTGTCCCTGCT-3’ 
AR R (F) 5’GACTCAGATGCTCCAACGCCTCCAC-3’ 
TMPRSS 2 
TMPRSS2 F 5’-AATCGGTGTGTTCGCCTCTAC-3’ 
TMPRSS2 R 5’-GCGGCTGTCACGATCC-3’ 
PSA 
PSA F 5’ TTGTCTTCCTCACCCTGTCC 3’ 
PSA R 5’ AGCTGTGGCTGACCTGAAAT 3’ 
KLK2 
KLK2 F 5’ CCTCACGTTCTGGCATCACTT 3’ 
KLK2 R 5’ CGGCCAGGTGAGTTCCAA 3’ 
PHB 3’UTR long 
PHB for 5’ GGCTGAGCAACAGAAAAAGG 3’ 
UTR rev 3 5’-ATACAAGTCCATCCAAGTTTTAGGACCCTG-3’ 
PHB 3’UTR mid 
PHB for 5’ GGCTGAGCAACAGAAAAAGG 3’ 
UTR rev 2 5’-CTCATCCGCAAACCTTCCATCAGTGACAG-3’ 
PHB 3’UTR short 
PHB for 5’ GGCTGAGCAACAGAAAAAGG 3’ 
UTR rev 1 5’-CTAATTAGAGATCTGAAGTGATTTTACCTT-3’ 
 
Primers Sequences used for SYBR Green qRT-PCR. This table relates to Experimental Procedures: MiR and mRNA Quantification by 
Quantitative Real-Time RT-PCR and Figs 2, 3, 4, 5, 6, S5 and S7.  
Table 3: MiR Oligonucleotide Sequences for Transfections  
 
Name Sequence 
miR-27a mimic 5’ TTCACAGTGGCTAAGTTCCGC 3’ 
miR-27a ASO 5’ GCGGAACTTAGCCACTGTGAA 3’ 
miR-27a ASO scram 5’ TGACCGTATAGGCTAAGCGAC 3’ 
 
Oligonucleotide Sequences used for MiR/ASO Transfections. This table relates to Experimental Procedures: Oligonucleotide 
Transfections and Fig 2.  
  
Table 4: Primer Sequences for qPCR Following Chromatin Immunoprecipitation  
 
Name Sequence 
miR prom ChIP for 5’-GCAGGTACCGTGCTGGGCACTTACTGAGTGA-3’ 
miR prom ChIP rev 5’-GCCACTTCCTAGAAGCCTGGAG-3’ 
 
Primers Sequences used for Chromatin ImmunoprecipitationSYBR Green qPCR. This table relates to Experimental Procedures: 
Chromatin Immunoprecipitation (ChIP) and Fig 5.  
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Supplemental Figure 1!
3kb PHB Prom! Luciferase!
Figure S1: Androgen signalling downregulates PHB promoter activity and Luciferase-PHB 3ʼUTR is 
expressed from the SV40 promoter of the SV40-GL4-PHB-3ʼUTR vector upon transient transfection into HeLa 
cells. (A) Relative luciferase activity was measured in serum-deprived Cos-1 cells co-transfected with 3kb proximal 
PHB promoter reporter construct and wild-type AR expression vector ± mibolerone (MB) (0-10nM) for 24h. β-
galactosidase activity was used as a control for cell number. Data represent mean relative luciferase activity for three 
independent experiments with duplicate analyses of each RNA sample ± SEM. (B) Diagram showing the structure of 
the SV40-GL4-PHB 3ʼUTR vector and regions amplified by primers used for RT-PCR. C) RT-PCR analysis of 
luciferase, PHB 3ʼUTR and luciferase-PHB 3ʼUTR from RNA from HeLa cells transiently transfected with SV40-GL4 
or SV40-GL4-PHB 3ʼUTR plasmids. * P ≤ 0.05. These data relate to Fig 1.!
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Supplemental Figure 2!
Figure S2: PHB 3ʼUTR is a predicted target of miR-27a. Diagram illustrating locations of predicted miR 
associations with the PHB-3ʼUTR. Data from http://microrna.org. These data relate to Fig 2.!
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Supplemental Figure 3!
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Figure S3:  MiR-27a and PHB overexpression do not alter prostate cancer cell growth in the absence of androgen. 
Sulphorhodamine B growth assays of LNCaP/TR2/p2TetR-miR-27a cells treated with 1µM dox to induce miR-27a 
expression and transfected with GFP-PHB (pcDNA4/TO-GFP-PHB) or empty pcDNA4/TO using Lipofectamine LTX. SRB 
assays were performed at 0, 1, 3, 5 and 7 days post-transfection/treatment. Bars: mean relative absorbance at 492nm, 
where absorbance at day 5 in absence of PHB was set at 1. Data represent mean relative absorbance at 492nm for three 
independent experiments ± SEM. These data relate to Fig 3.!
!
Supplemental Figure 4!
Figure S4: The miR-23a27a24-2 promoter contains putative AREs and AR is recruited to the PSA Gene Promoter 
in the Presence of Androgen. (A) Diagram illustrating the location of predicted AREs within the miR-23a27a24-2 
proximal promoter. Primers used for chromatin immunoprecipitation are indicated by small black arrows. AREs were 
predicted using the ALGGEN algorithm (http://alggen.lsi.upc.es/). (B,C,D,E) ChIP analysis of AR recruitment to AREs of 
the PSA promoter in LNCaP cells treated with MB (10nM) for 0-2h. The purified DNA fraction was probed for presence of 
PSA ARE1 (B), PSA ARE2 (C), PSA ARE negative region (D) and PSA ARE3 (enhancer) (E) by qPCR. AR relative 
enrichment represents AR recruitment to promoter regions relative to input levels. Data represent mean relative AR 
enrichment for three independent experiments ± SEM. * P ≤ 0.05. These data relate to Fig 5.!
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Supplemental Figure 5!
Figure S5: Androgen Treatment Increases Expression of PSA. qRT-PCR analysis of PSA from LNCaP 
cells treated with MB (10nM) or an equal volume of ethanol for 0-24h. L19 was used as a normalisation gene. 
Data represent mean of three independent experiments ± SEM. ** P ≤ 0.001 relative to 0h/untreated samples. 
These data relate to Fig 5.!
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Supplemental Figure 6!
A!
B!
Figure S6: PrimiR-23a27a24-2-specific Drosha reporter activity is not altered in the absence of androgen or in 
the presence of empty CMV-GL4 vector. Luciferase activity in extracts of Cos-1 cells transfected with either (A) 
100ng CMV-PrimiR-23a27a24-2-GL4 (primiR-23a27a24-2-specific Drosha cleavage reporter) in the absence of AR, or 
(B) 100ng empty CMV-GL4 vector and wild-type AR expression construct pSVAR, and treated with 1-10nM 
Mibolerone (MB) ± 1-10µM Bicalutamide (Bic) or vehicle (EtOH) for 24h. Luciferase was normalised for transfection 
efficiency (β-galactosidase activity) and mean ± SEM of three independent experiments is shown.  These data relate 
to Fig 5.!
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Supplemental Figure 7!
Figure S7. Transcript levels of the androgen-regulated gene, KLK2, are reduced in prostate cancer cells 
treated with actinomycin D ± MB. qRT-PCR analysis of KLK2 levels from LNCaP cells grown in stripped medium and 
treated with Actinomycin D (1µM) and MB (1nM) or ethanol for 0-48h. Reverse transcription was performed using oligo 
d(T) primers. Data represents mean relative gene expression for three independent experiments ± SEM. * P ≤ 0.05. 
These data relate to Fig 6.!
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